A detailed history of Advisor Group Holdings, Inc. transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 3,772 shares of CHRS stock, worth $6,450. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,772
Previous 3,772 -0.0%
Holding current value
$6,450
Previous $6,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.58 - $2.51 $287 - $456
-182 Reduced 4.6%
3,772 $6,000
Q1 2024

May 10, 2024

BUY
$2.02 - $3.14 $1,139 - $1,770
564 Added 16.64%
3,954 $9,000
Q4 2023

Feb 12, 2024

SELL
$1.59 - $3.85 $675 - $1,636
-425 Reduced 11.14%
3,390 $11,000
Q3 2023

Nov 13, 2023

BUY
$3.74 - $5.45 $7,498 - $10,927
2,005 Added 110.77%
3,815 $14,000
Q4 2022

Feb 10, 2023

BUY
$5.69 - $10.07 $9,820 - $17,380
1,726 Added 2054.76%
1,810 $14,000
Q2 2022

Aug 10, 2022

SELL
$5.86 - $13.23 $2,853 - $6,443
-487 Reduced 85.29%
84 $1,000
Q1 2022

May 04, 2022

SELL
$10.92 - $16.41 $5,973 - $8,976
-547 Reduced 48.93%
571 $8,000
Q3 2021

Nov 05, 2021

BUY
$12.68 - $17.79 $4,729 - $6,635
373 Added 50.07%
1,118 $17,000
Q2 2021

Aug 02, 2021

BUY
$12.95 - $15.41 $3,962 - $4,715
306 Added 69.7%
745 $10,000
Q1 2021

May 13, 2021

BUY
$14.42 - $21.39 $3,403 - $5,048
236 Added 116.26%
439 $6,000
Q4 2020

Feb 10, 2021

SELL
$16.56 - $18.94 $13,943 - $15,947
-842 Reduced 80.57%
203 $4,000
Q3 2020

Nov 12, 2020

BUY
$17.41 - $19.89 $8,705 - $9,945
500 Added 91.74%
1,045 $19,000
Q2 2020

Aug 14, 2020

SELL
$14.43 - $19.16 $66,666 - $88,519
-4,620 Reduced 89.45%
545 $10,000
Q1 2020

May 18, 2020

BUY
$11.67 - $22.53 $60,275 - $116,367
5,165 New
5,165 $82,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $133M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.